Free Trial

Terns Pharmaceuticals (TERN) Competitors

Terns Pharmaceuticals logo
$3.90 -0.10 (-2.50%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$3.90 0.00 (0.00%)
As of 06/20/2025 04:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TERN vs. JANX, VERA, ANIP, OCUL, BGM, TVTX, CVAC, AMPH, CALT, and GPCR

Should you be buying Terns Pharmaceuticals stock or one of its competitors? The main competitors of Terns Pharmaceuticals include Janux Therapeutics (JANX), Vera Therapeutics (VERA), ANI Pharmaceuticals (ANIP), Ocular Therapeutix (OCUL), Qilian International Holding Group (BGM), Travere Therapeutics (TVTX), CureVac (CVAC), Amphastar Pharmaceuticals (AMPH), Calliditas Therapeutics AB (publ) (CALT), and Structure Therapeutics (GPCR). These companies are all part of the "pharmaceutical products" industry.

Terns Pharmaceuticals vs. Its Competitors

Terns Pharmaceuticals (NASDAQ:TERN) and Janux Therapeutics (NASDAQ:JANX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, community ranking, valuation, analyst recommendations, media sentiment, profitability and earnings.

98.3% of Terns Pharmaceuticals shares are held by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are held by institutional investors. 1.5% of Terns Pharmaceuticals shares are held by insiders. Comparatively, 29.4% of Janux Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Terns Pharmaceuticals had 3 more articles in the media than Janux Therapeutics. MarketBeat recorded 7 mentions for Terns Pharmaceuticals and 4 mentions for Janux Therapeutics. Terns Pharmaceuticals' average media sentiment score of 1.25 beat Janux Therapeutics' score of 0.91 indicating that Terns Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Terns Pharmaceuticals
4 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Janux Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Janux Therapeutics has higher revenue and earnings than Terns Pharmaceuticals. Janux Therapeutics is trading at a lower price-to-earnings ratio than Terns Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Terns PharmaceuticalsN/AN/A-$88.85M-$1.09-3.58
Janux Therapeutics$10.59M131.86-$68.99M-$1.36-17.35

Terns Pharmaceuticals has a beta of -0.18, meaning that its stock price is 118% less volatile than the S&P 500. Comparatively, Janux Therapeutics has a beta of 2.97, meaning that its stock price is 197% more volatile than the S&P 500.

Terns Pharmaceuticals presently has a consensus price target of $15.63, indicating a potential upside of 300.64%. Janux Therapeutics has a consensus price target of $95.25, indicating a potential upside of 303.60%. Given Janux Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Janux Therapeutics is more favorable than Terns Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Terns Pharmaceuticals
0 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.60
Janux Therapeutics
0 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
3.09

Terns Pharmaceuticals has a net margin of 0.00% compared to Janux Therapeutics' net margin of -463.91%. Janux Therapeutics' return on equity of -9.29% beat Terns Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Terns PharmaceuticalsN/A -28.81% -27.55%
Janux Therapeutics -463.91%-9.29%-8.89%

Terns Pharmaceuticals and Janux Therapeutics both received 44 outperform votes by MarketBeat users. However, 69.84% of users gave Janux Therapeutics an outperform vote while only 59.46% of users gave Terns Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Terns PharmaceuticalsOutperform Votes
44
59.46%
Underperform Votes
30
40.54%
Janux TherapeuticsOutperform Votes
44
69.84%
Underperform Votes
19
30.16%

Summary

Janux Therapeutics beats Terns Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

Get Terns Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for TERN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TERN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TERN vs. The Competition

MetricTerns PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$340.63M$2.82B$5.18B$8.55B
Dividend YieldN/A2.69%5.38%4.21%
P/E Ratio-3.5820.9225.7219.15
Price / SalesN/A302.70414.02109.91
Price / CashN/A40.9225.4426.73
Price / Book0.967.427.925.78
Net Income-$88.85M-$55.10M$3.15B$248.44M
7 Day Performance-2.74%-2.51%-0.66%-0.29%
1 Month Performance29.14%6.09%4.55%3.92%
1 Year Performance-46.06%-1.66%41.89%15.59%

Terns Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TERN
Terns Pharmaceuticals
4.3988 of 5 stars
$3.90
-2.5%
$15.63
+300.6%
-46.1%$340.63MN/A-3.5840Positive News
JANX
Janux Therapeutics
2.7184 of 5 stars
$23.61
-5.2%
$95.25
+303.4%
-42.4%$1.40B$9.34M-20.1830
VERA
Vera Therapeutics
2.6036 of 5 stars
$21.85
-3.9%
$65.00
+197.5%
-41.9%$1.39BN/A-8.3740Short Interest ↑
ANIP
ANI Pharmaceuticals
3.5888 of 5 stars
$64.29
+2.8%
$80.13
+24.6%
+12.0%$1.39B$674.07M-116.89600Positive News
OCUL
Ocular Therapeutix
3.542 of 5 stars
$8.75
+0.2%
$16.25
+85.7%
+30.1%$1.39B$59.65M-6.63230Positive News
BGM
Qilian International Holding Group
N/A$14.10
+4.4%
N/AN/A$1.37B$25.10M0.00298Gap Up
High Trading Volume
TVTX
Travere Therapeutics
2.5054 of 5 stars
$14.68
+1.2%
$32.14
+119.0%
+95.8%$1.30B$273.53M-3.58460
CVAC
CureVac
4.5362 of 5 stars
$5.52
-0.9%
$9.00
+63.0%
+66.9%$1.24B$523.70M10.04880
AMPH
Amphastar Pharmaceuticals
4.2119 of 5 stars
$25.98
+0.6%
$32.33
+24.5%
-39.3%$1.22B$730.66M8.661,620Positive News
CALT
Calliditas Therapeutics AB (publ)
N/A$40.00
flat
N/AN/A$1.19B$1.60B-21.62180
GPCR
Structure Therapeutics
1.6616 of 5 stars
$20.57
-5.1%
$76.50
+271.9%
-52.3%$1.18BN/A-27.80136

Related Companies and Tools


This page (NASDAQ:TERN) was last updated on 6/23/2025 by MarketBeat.com Staff
From Our Partners